EtodolacThird Party Manufacturing in India

Etodolac works by inhibiting the cyclooxygenase (COX) enzymes, with preferential selectivity for COX-2 over COX-1. These enzymes are responsible for converting arachidonic acid into prostaglandins, which are chemical mediators that cause pain, inflammation, and fever. By binding to the upper portion of the COX enzyme active site, etodolac prevents arachidonic acid from entering, thereby reducing prostaglandin synthesis. This mechanism produces analgesic, anti-inflammatory, and antipyretic effects. Etodolac belongs to the pyranocarboxylic acid class of NSAIDs and was previously thought to be a non-selective COX inhibitor, but subsequent studies have demonstrated it is 5 to 50 times more selective for COX-2 than COX-1. This relative COX-2 selectivity gives etodolac a favorable gastrointestinal safety profile compared to traditional non-selective NSAIDs. The drug is extensively metabolized in the liver and has an elimination half-life of approximately 6 to 7 hours, supporting twice-daily or thrice-daily dosing regimens for chronic conditions like osteoarthritis and rheumatoid arthritis.

Therapeutic Uses

Etodolac is prescribed for the treatment of:

• Osteoarthritis: Provides effective relief from joint pain, stiffness, and swelling associated with osteoarthritis, improving mobility and quality of life for patients.
• Rheumatoid Arthritis: Reduces inflammation, pain, and morning stiffness in rheumatoid arthritis, helping manage this chronic autoimmune condition.
• Acute Pain: Used for short-term management of mild to moderate acute pain, including musculoskeletal injuries and post-surgical discomfort.

Why Manufacturers Choose Etodolac

Etodolac occupies a valuable position in the analgesic market as a NSAID with preferential COX-2 selectivity, offering a favorable balance of efficacy and gastrointestinal tolerability. Its established safety profile and inclusion in major pharmacopoeias (IP, USP, BP) make it a preferred molecule for PCD franchise operators and third-party manufacturers across India. The consistent clinical demand for osteoarthritis and rheumatoid arthritis treatments ensures steady prescription volumes, while the 400mg tablet strength is a standardized dosage form that can be efficiently produced using conventional tablet compression technology. Indian manufacturers benefit from well-established supply chains for the API and excipients, competitive production costs, and growing export opportunities to regulated markets. The molecule is particularly attractive for companies targeting the geriatric patient segment, where chronic pain management represents a significant therapeutic need.

This makes Etodolac one of the most sought-after molecules for third party manufacturing in India, with consistent demand from PCD franchise operators and export-oriented companies.